More recently, an anti-CCR7 antibody was used to reduce CLL migration to the lymph nodes and the anticipated clinical trials will further examine the efficacy/safety of this anti-CCR7 therapy [309]. The gene discussed is CCR7; the disease is B-cell chronic lymphocytic leukemia.